Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
4.350
-0.030 (-0.68%)
Jun 24, 2025, 4:00 PM - Market closed
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-$826,308
Market Cap
156.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
EPRX News
- 22 days ago - Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewsWire
- 6 weeks ago - Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewsWire
- 7 weeks ago - Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May - GlobeNewsWire
- 3 months ago - Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Announces CFO Succession - PRNewsWire
- 7 months ago - Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - PRNewsWire